All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Fixed-Duration Glofitamab Elicits Early, Durable Complete Remissions in Relapsed/Refractory LBCL

September 2nd 2022

Michael Dickinson, MBBS, expands on data from a phase 2 dose-expansion study of glofitamab in heavily pretreated, highly refractory large B-cell lymphoma, explains the effect bispecific antibodies could have on treatment, and highlights other research efforts surrounding glofitamab-based therapies.

Metastatic Breast Cancer Enters a New Era of HER2 Classification

September 2nd 2022

A dramatic presentation at the 2022 American Society of Clinical Oncology Annual Meeting changed treatment standards seemingly overnight for women with previously treated metastatic HER2-low breast cancer. However, fundamental questions remain.

Lapatinib May Boost Effectiveness of Drugs That Destroy Cancer Proteins by Blocking Resistance

September 2nd 2022

Researchers at Fox Chase Cancer Center have discovered that the drug efflux pump MDR1 promotes resistance to a promising new class of drugs called PROTACS—proteolysis-targeting chimeras.

ASTRO Releases Clinical Guidelines for Radiation Therapy in IDH-Mutant Glioma

September 1st 2022

For the first time, the American Society for Radiation Oncology has issued recommendations on the use of radiation therapy to treat patients with IDH-mutant grade 2 and grade 3 diffuse glioma, including oligodendroglioma and astrocytoma.

SEL24/MEN1703 Demonstrates Early Efficacy, Tolerability in R/R AML With IDH1/2 Mutations

September 1st 2022

The first-in-class dual PIM/FLT3 kinase inhibitor, SEL24/MEN1703, showcased encouraging efficacy and a tolerable safety profile in patients with acute myeloid leukemia whose tumors harbor a IDH1/2 mutation.

Biomarker-Directed Therapy in Multiple Myeloma Signals the Future of the Field

September 1st 2022

Shaji Kumar, MD, and Jonathan Kaufman, MD, review the advances with translocations such as t(11;14), treating practices, and emerging markers in multiple myeloma.

Erlotinib Displays Long-Term DFS Benefit, Meaningful OS Improvement vs Chemotherapy in EGFR+ NSCLC

September 1st 2022

Erlotinib continued to elicit a disease-free survival and overall survival benefit vs vinorelbine/cisplatin chemotherapy in patients with EGFR-positive non–small cell lung cancer, according to updated OS data and an exploratory analysis from the phase 2 EVAN trial.

Single-Agent Belantamab Mafodotin Elicits Activity in Heavily Pretreated Patients With R/R Myeloma

September 1st 2022

Belantamab mafodotin monotherapy demonstrated anticancer activity with a tolerable safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma.

Liver Cancer’s Changing Therapeutic Landscape

September 1st 2022

New treatments, particularly immunotherapies, are providing durable benefits for patients with hepatocellular carcinoma.

Neoadjuvant Chemotherapy Elicits Necessary Responses for Organ-Sparing Surgery in Early-Stage Rectal Cancer

September 1st 2022

Chemotherapy prior to transanal excision surgery demonstrated favorable responses that led to increased organ preservation rates among patients with early rectal cancer, according to findings from the phase 2 NEO trial.

Daratumumab-Containing Regimens Display PFS Benefit Across Myeloma Subgroups

September 1st 2022

Daratumumab combinations elicited significant progression-free survival, overall survival, overall response rate, and minimal residual disease–negativity benefits vs control in pretreated patients with relapsed or refractory multiple myeloma across clinically relevant subgroups.

CTCL Is Rare, Incurable, and Potentially Lethal in Advanced Stages

August 31st 2022

Although cutaneous T-cell lymphoma, a group of non-Hodgkin T-cell lymphomas, remains a rare disease, incidence has increased steadily since the 1970s.

Approval Sought for Tafasitamab/Lenalidomide Combo in R/R DLBCL in Hong Kong

August 31st 2022

The Hong Kong Special Administrative Region’s Department of Health has accepted for review a biologics license application seeking the approval of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.

Frontline Pivekimab Sunirine Demonstrates Significant Activity in Blastic Plasmacytoid Dendritic Cell Neoplasm

August 31st 2022

First-line treatment with pivekimab sunirine generated responses with favorable tolerability in patients with blastic plasmacytoid dendritic cell neoplasm, according to data from the phase 2 CADENZA trial.

Benefit of Daratumumab Plus RVd Is Maintained Without Additional Toxicities Among Black Patients With NDMM

August 31st 2022

A subgroup analysis of the phase 2 GRIFFIN trial confirmed that Black patients with newly diagnosed multiple myeloma elicited a benefit from treatment with daratumumab added to lenalidomide, bortezomib, and dexamethasone without additional toxicities.

Florida Cancer Specialists & Research Institute Appoints New Members to Senior Management

August 31st 2022

Florida Cancer Specialists & Research Institute is pleased to welcome Jon Meyers, Nicole Radford, FACHE, MS, MT(ASCP), Bob Simon, Paul D. Summitt, and Samantha Watkins to its senior management team.

Vopratelimab Plus Pimivalimab Fails to Meet Tumor Reduction End Point in Select Metastatic NSCLC

August 31st 2022

The addition of vopratelimab to pimivalimab did not elicit a significant mean percent change of baseline tumor size in all measurable lesions vs pimivalimab alone in patients with immunotherapy-naïve, metastatic non–small cell lung cancer who were positive for the TISvopra predictive biomarker.

Sotorasib Meets PFS End Point in Previously Treated, KRAS G12C–Mutated NSCLC

August 31st 2022

Sotorasib demonstrated superiority and a statistically significant benefit in progression-free survival vs standard-of-care docetaxel in previously treated patients with KRAS G12C–mutated non–small cell lung cancer.

Subcutaneous Isatuximab Elicits Comparable Efficacy, Safety to IV Formulation in Relapsed/Refractory Myeloma

August 31st 2022

Subcutaneous administration of isatuximab through a syringe pump or on-body delivery system demonstrated similar efficacy and safety compared with intravenous isatuximab when combined with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Frontline Gefitinib Plus Chemotherapy Improves PFS2 Vs Gefitinib Alone in EGFR-Mutated NSCLC

August 30th 2022

The combination of gefitinib plus chemotherapy generated a benefit in time to second progression vs gefitinib alone in untreated patients with EGFR-mutated non–small cell lung cancer.